

ASX RELEASE

17 April 2020

KAZIA THERAPEUTICS LIMITED (ASX: KZA; NASDAQ: KZIA) - CLEANSING NOTICE

This notice is given by Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA) (**Company**) under section 708A(5)(e) of the *Corporations Act 2001* (Cth) (**Corporations Act**).

The Company has today issued 18,041,667 fully paid ordinary shares (**New Shares**) under a placement to professional and sophisticated investors at an issue price of A\$0.40 per New Share. The Placement was announced on Wednesday, 8 April 2020, together with a Share Purchase Plan to existing eligible shareholders.

The proceeds from the Placement and the Share Purchase Plan will be used to further the Company's ongoing clinical studies and for general working capital purposes.

In accordance with section 708A(6) of the Corporations Act, the Company advises that:

- (a) the New Shares were issued without disclosure to investors under Part 6D.2 of the Corporations Act;
- (b) this notice is being given under section 708A(5)(e) of the Corporations Act;
- (c) as at the date of this notice, the Company has complied with:
 - (i) the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and
 - (ii) section 674 of the Corporations Act; and
- (d) as at the date of this notice, there is no information that is "excluded information" within the meaning of sections 708A(7) or 708A(8) of the Corporations Act.

Yours sincerely



Kate Hill
Company Secretary
Kazia Therapeutics Limited